GCL
APGE icon

Glazer Capital LLC’s Apogee Therapeutics APGE Stock Holding History

Glazer Capital LLC’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218M Buy
+1,641,042
New +$148M 5.36% 3

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Glazer Capital LLC's APGE Position: Q2 2026 in Review

Glazer Capital LLC opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 1,641,042 shares worth $218M. The stake represents 5.36% of the portfolio and ranks #3 among its holdings.

283 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Glazer Capital LLC held 1,641,042 shares of Apogee Therapeutics worth $218M as of Q2 2026.
  • Apogee Therapeutics was a new Glazer Capital LLC position in Q2 2026.
  • Apogee Therapeutics made up 5.36% of Glazer Capital LLC's portfolio in Q2 2026, its #3 holding.
  • 283 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Glazer Capital LLC's 13F filing for Q2 2026, filed 17 Aug 2026.